These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2015-002070-21||Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor||2019-01-02||due-trials|
|Other||2019-001043-41||A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinu...||not-yet-due|
|Reported results||2019-003898-26||A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE MASS BALANCE, ROUTE OF ELIMINATION, AND METABOLIC PROFILE OF [14C] LABELED MGCD516 MALATE SALT IN HEALTHY MALE SUBJECTS||2020-02-03||due-trials|
|Ongoing||2020-003101-58||A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation||not-yet-due|
|Ongoing||2020-003645-11||A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation||not-yet-due|
|Ongoing||2020-004048-27||A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standar...||not-yet-due|